Comparative Pharmacology
Head-to-head clinical analysis: SUMYCIN versus TETRACYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUMYCIN versus TETRACYN.
SUMYCIN vs TETRACYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the A site.
250-500 mg orally every 6 hours or 500 mg orally every 12 hours (maximum 2 g/day)
250–500 mg orally every 6 hours; or 500 mg to 1 g intravenously every 6–12 hours (administer slow IV).
None Documented
None Documented
6-12 hours; prolonged in renal impairment (up to 24-48 hours in anuria)
Terminal elimination half-life: 6-8 hours in normal renal function; prolonged to 18-30 hours in severe renal impairment (CrCl <30 mL/min); dosing adjustment required.
Renal (60-80% unchanged via glomerular filtration), biliary/fecal (20-40%)
Renal (glomerular filtration): 60% unchanged in urine; biliary/fecal: 40% as active drug and metabolites; enterohepatic recirculation occurs.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic